Ciclosporin intravenous - Maas Biolab/NeuroVive

Drug Profile

Ciclosporin intravenous - Maas Biolab/NeuroVive

Alternative Names: CicloMulsion; Ciclosporin-A; Cyclosporin - Maas Biolab; Cyclosporin-A; Mitogard; Neuro-STAT®; NeuroSTAT

Latest Information Update: 16 Jun 2017

Price : $50

At a glance

  • Originator Maas Biolab; NeuroVive Pharmaceutical
  • Developer Defense Threat Reduction Agency; Maas Biolab; NeuroVive Pharmaceutical; Skane University Hospital; Walter Reed Army Institute of Research
  • Class Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Neuroprotectants
  • Mechanism of Action Calcineurin inhibitors; Cyclophilin inhibitors; Free radical inhibitors; Immunosuppressants; Mitochondrial permeability transition pore inhibitors; P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis; Brain injuries
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Brain injuries
  • Preclinical Amyotrophic lateral sclerosis; Poisoning
  • Discontinued Acute kidney injury; Reperfusion injury

Most Recent Events

  • 23 May 2017 Positive efficacy data from a phase IIa CHIC trial in Brain injuries (traumatic) released by NeuroVive
  • 23 May 2017 NeuroVive terminates the phase IIa CHIC trial in Brain injuries in Denmark in advance to focus its efforts on preparing for the next clinical study with ciclosporin for traumatic brain injury, based on positive results from this trial and preclinical studies (IV) (NCT01825044)
  • 25 Oct 2016 NeuroVive Pharmaceutical terminates its agreement with Hospices Civils de Lyon and OPeRa for CicloMulsion®
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top